Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Harrow Health, Inc.NASDAQ: HROW
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns negative
Q1 FY2026 free cash flow was -$9.19M, compared with $19.46M a year earlier. Trailing-twelve-month free cash flow was $14.28M.
Context
- Free cash flow amounted to 15.7% of revenue in FY2025, down 14.8 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near -$9.19M or moves back toward the trailing-twelve-month quarterly average of $3.57M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 42.76M USD
- Year-over-year change
- +170.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.76M | +170.2% |
| FY2024 | 2024-12-31 | (60.88M) | +59.1% |
| FY2023 | 2023-12-31 | (148.71M) | -2350.8% |
| FY2022 | 2022-12-31 | (6.07M) | +74.1% |
| FY2021 | 2021-12-31 | (23.43M) | — |
Free Cash Flow vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +139.0% is the 3rd highest of 8, against a peer median of +62.3%.
- Free cash flow amounts to 5.3% of revenue for HROW, versus a peer median of 2014.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.54M USD | +79.5% | +53.6% | 3565.9% | |
| LTM Mar 2026 | $240.94M USD | +62.3% | +50.7% | 463.0% | |
| LTM Sep 2026 | $172.81M USD | +35.8% | -18.7% | — | |
| LTM Jun 2026 | $140.33M USD | +185.0% | — | 2.6% | |
| LTM Mar 2026 | CHF 62.47M CHF | +14.4% | +29.7% | 12395.4% | |
| LTM Mar 2026 | $47.05M USD | -26.5% | -2.9% | 14121.8% | |
| LTM Sep 2026 | $32.44M USD | +151.9% | -23.3% | 4.8% | |
| LTM Mar 2026 | $14.28M USD | +139.0% | — | 5.3% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.9M USD | — | — | — |
| Peer median (excluding HROW) | — | +62.3% | +13.4% | 2014.4% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Depreciation & Amortization | 2.4M | 3.67M | 12.34M | 14.54M | 19.68M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.75M | 7.97M | 15.7M | 17.62M | 12.5M |
| Change in Working Capital | (253K) | (5.57M) | (7.14M) | (44.63M) | 185K |
| Accounts Receivables | (1.83M) | (1.86M) | (30.34M) | (80.23M) | 5.01M |
| Inventory | (255K) | (2.32M) | (4.33M) | 165K | (2.82M) |
| Accounts Payables | 1.73M | 933K | 31.8M | 37.5M | (4.61M) |
| Other Working Capital | 103K | (2.32M) | (4.26M) | (2.06M) | 2.6M |
| Other Non-Cash Items | 15.2M | 9.72M | 7.35M | 7.75M | 16.64M |
| Operating Cash Flow | 5.08M | 1.71M | 3.84M | (22.2M) | 43.86M |
| Capital Expenditures | (28.51M) | (7.77M) | (152.55M) | (38.67M) | (1.1M) |
| Acquisitions (Net) | 9.83M | 0 | 0 | 0 | (4.36M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 9.83M | 0 | 0 | 5.51M | 0 |
| Other Investing Activities | (36.55M) | 854K | (151.09M) | (37.08M) | (215K) |
| Investing Cash Flow | (18.69M) | (1.74M) | (152.55M) | (33.16M) | (5.46M) |
| Debt Repayment | 71.07M | 31.72M | 74.64M | 29.78M | 11.84M |
| Common Stock Issued | 0 | 22.66M | 64.52M | 0 | 467K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (127K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | (234K) | (12.63M) | (1.25M) | (25.04M) |
| Financing Cash Flow | 51.47M | 54.14M | 126.53M | 28.53M | (12.72M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.87M | 54.1M | (22.19M) | (26.84M) | 25.68M |
| Free Cash Flow | (23.43M) | (6.07M) | (148.71M) | (60.88M) | 42.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.